Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen RAVICTI — Rest of World (ROW) sales by Year
RAVICTI — Rest of World (ROW) sales ($M) ($M)
Amgen RAVICTI — Rest of World (ROW) sales: $21M in FY2025, up 31.3% from a year earlier.
Latest, FY2025
21
Period ended Dec 31, 2025
Change on a year earlier
+31.3%
16 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| RAVICTI — ROW (1) | 21 | 31 | % | 16 | * | 1”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Other Product Sales by Geographic Region Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RAVICTI — Rest of World (ROW) sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21 | +31.3% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 16 | +1,500.0% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 1 | – | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
Cite this data
StockData. (2026). Amgen RAVICTI — Rest of World (ROW) sales ($M), annual FY2023–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-ravicti-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.